表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗联合常规化疗对肺癌的临床效果观察

Clinical effect of epidermal growth factor receptor-tyrosine kinase inhibitor targeting therapy combined with conventional chemotherapy in non-small cell lung cancer

目的探讨表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)靶向治疗联合常规化疗在非小细胞肺癌中的临床效果。方法根据治疗方案的不同将81例非小细胞肺癌患者分为观察组(n=42)和对照组(n=39)。观察组接受EGFR-TKI靶向治疗联合常规化疗,对照组接受EGFR-TKI靶向治疗。比较两组患者的近期疗效、不良反应发生情况和无进展生存情况。比较治疗前后两组患者的血清癌胚抗原(CEA)和细胞角质蛋白19片段抗原21-1(CYFRA21-1)水平。结果观察组患者的治疗总有效率为71.43%(30/42),对照组患者的治疗总有效率为51.28%(20/39)。观察组患者的近期疗效优于对照组患者(P﹤0.05)。治疗后,观察组患者的血清CYFRA21-1、CEA水平均明显低于对照组患者(P﹤0.01)。两组患者的各不良反应发生率比较,差异均无统计学意义(P﹥0.05)。观察组患者的中位无进展生存期明显长于对照组患者(P﹤0.01)。结论EGFR-TKI靶向治疗联合常规化疗在非小细胞肺癌的治疗中具有较好的效果,值得临床应用。

Objective To explore the clinical effect of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)targeting therapy combined with conventional chemotherapy in non-small cell lung cancer.Method Eightyone patients with non-small cell lung cancer were divided into observation group(n=42)and control group(n=39),treated with EGFR-TKI targeting therapy combined with conventional chemotherapy and EGFR-TKI targeting therapy,respectively.The short-term therapeutic effect,adverse reactions and progression free survival were compared between the two groups;the carcinoembryonic antigen(CEA)and serum cytokeratin 19 fragment(CYFRA21-1)were compared between the two groups before and after treatment.Result The total effective rate was 71.43%(30/42)in the observation group and 51.28%(20/39)in the control group.The short-term efficacy of the observation group was better than that of the control group(P<0.05).The level of serum CYFRA21-1 and CEA in the observation group after treatment were significantly lower than those in the control group(P<0.01);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05);the median progression free survival time of the observation group was significantly longer than that of the control group(P<0.01).Conclusion EGFR-TKI targeting therapy combined with conventional chemotherapy in the treatment of non-small cell lung cancer has a good effect,which is worthy of clinical application.